… About ProQR Therapeutics An innovative biotech company advancing … Axiomer RNA-editing platform technology. We are ProQR We are ProQR We are ProQR, a biotechnology company dedicated to …
… ProQR founding story When our CEO, Daniel A. de Boer, knew … his newborn son had an incurable rare disease, he founded ProQR to help people like his son. Learn more. A personal … a difference in the world. Daniel continues to motivate ProQRians to remind them of the company’s mission and to …
… ProQR and Galapagos Announce Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer® technology LEIDEN, the Netherlands, Jan. 08, … fibrosis targets,” said Daniel A. de Boer, CEO of ProQR. “We look forward to working closely with the team at …
… ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets Agreement … FERRAND, France, Aug. 01, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company …
… ProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day LEIDEN, … in non-core therapeutic areas and non-rare diseases. “The ‘ProQR Vision 2023’ strategy presents a clear path for ProQR …
Access based on positive interim analysis of clinical data as well as preclinical data to date PRIME designation provides a pathway for frequent and early interactions with the EMA aimed at supporting accelerated evaluation and approval
… ProQR’s Drug Candidate QRX-411 for Usher Syndrome Receives … Orphan Drug Designation from FDA and EMA Key Updates ProQR’s QRX-411 receives Orphan Drug Designation by the FDA …
